Royalty Pharma plc (MUN:RPD)
Germany
· Delayed Price · Currency is EUR 33.50
-0.56 (-1.64%)
At close: Jan 2, 2026
Royalty Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 618.7 | 929.03 | 477.01 | 1,711 | 1,541 | Upgrade
|
| Short-Term Investments | 18.8 | 58.2 | 18.3 | 25.72 | 647.87 | Upgrade
|
| Cash & Short-Term Investments | 637.5 | 987.23 | 495.31 | 1,736 | 2,189 | Upgrade
|
| Cash Growth | -35.43% | 99.31% | -71.48% | -20.67% | 6.16% | Upgrade
|
| Accounts Receivable | 883.7 | 810.73 | 760.84 | 727.92 | 682.66 | Upgrade
|
| Receivables | 883.7 | 810.73 | 760.84 | 727.92 | 682.66 | Upgrade
|
| Other Current Assets | 6.89 | 4.19 | 18.04 | 90.52 | 6.63 | Upgrade
|
| Total Current Assets | 1,528 | 1,802 | 1,274 | 2,555 | 2,878 | Upgrade
|
| Property, Plant & Equipment | 19.1 | - | - | - | - | Upgrade
|
| Long-Term Investments | 880.28 | 1,260 | 1,012 | 735.82 | 909.59 | Upgrade
|
| Goodwill | 924.63 | - | - | - | - | Upgrade
|
| Other Intangible Assets | - | 5.32 | 1.78 | 14.5 | 5.67 | Upgrade
|
| Long-Term Accounts Receivable | 16,208 | 15,127 | 14,089 | 13,493 | 13,718 | Upgrade
|
| Other Long-Term Assets | 60.19 | 28.21 | 4.74 | 15.13 | 4.14 | Upgrade
|
| Total Assets | 19,621 | 18,223 | 16,382 | 16,813 | 17,516 | Upgrade
|
| Accounts Payable | 19.4 | 13.37 | 15.17 | 7.91 | 5.62 | Upgrade
|
| Accrued Expenses | 110.82 | 98.06 | 51.68 | 54.16 | 57.7 | Upgrade
|
| Current Portion of Long-Term Debt | 380 | 997.77 | - | 997.51 | - | Upgrade
|
| Current Portion of Leases | 3.16 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 122.83 | 144.41 | 94.53 | 107.2 | 107.93 | Upgrade
|
| Total Current Liabilities | 636.21 | 1,254 | 161.38 | 1,167 | 171.25 | Upgrade
|
| Long-Term Debt | 8,571 | 6,615 | 6,135 | 6,119 | 7,096 | Upgrade
|
| Long-Term Leases | 16.1 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 682.61 | 12.08 | 0.9 | 2.5 | - | Upgrade
|
| Total Liabilities | 9,906 | 7,880 | 6,298 | 7,288 | 7,267 | Upgrade
|
| Common Stock | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | Upgrade
|
| Additional Paid-In Capital | 4,123 | 4,103 | 4,011 | 3,666 | 3,508 | Upgrade
|
| Retained Earnings | 2,356 | 2,846 | 2,518 | 1,965 | 2,255 | Upgrade
|
| Treasury Stock | -2.61 | -2.66 | -2.63 | -2.81 | -2.72 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | 16.49 | Upgrade
|
| Total Common Equity | 6,477 | 6,947 | 6,526 | 5,628 | 5,777 | Upgrade
|
| Minority Interest | 3,238 | 3,396 | 3,558 | 3,897 | 4,472 | Upgrade
|
| Shareholders' Equity | 9,715 | 10,342 | 10,084 | 9,525 | 10,249 | Upgrade
|
| Total Liabilities & Equity | 19,621 | 18,223 | 16,382 | 16,813 | 17,516 | Upgrade
|
| Total Debt | 8,970 | 7,612 | 6,135 | 7,116 | 7,096 | Upgrade
|
| Net Cash (Debt) | -8,333 | -6,625 | -5,640 | -5,380 | -4,907 | Upgrade
|
| Net Cash Per Share | -14.76 | -11.15 | -9.35 | -12.28 | -11.83 | Upgrade
|
| Filing Date Shares Outstanding | 428.42 | 433.32 | 446.69 | 443.17 | 432.96 | Upgrade
|
| Total Common Shares Outstanding | 428.67 | 445.99 | 446.69 | 443.17 | 432.96 | Upgrade
|
| Working Capital | 891.88 | 548.52 | 1,113 | 1,388 | 2,707 | Upgrade
|
| Book Value Per Share | 15.11 | 15.58 | 14.61 | 12.70 | 13.34 | Upgrade
|
| Tangible Book Value | 5,552 | 6,941 | 6,525 | 5,614 | 5,771 | Upgrade
|
| Tangible Book Value Per Share | 12.95 | 15.56 | 14.61 | 12.67 | 13.33 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.